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Introduction

1
Rheumatoid arthritis is associated with a 30-60% increased risk of cardiovascular events [1] [2] 6] and a 50% increased risk of death from cardiovascular disease [7] . Glucocorticoids are 3 often prescribed to patients with rheumatoid arthritis, but there are concerns regarding 4 potential adverse cardiovascular events in these patients already at high cardiovascular risk 5 [8, 9] . While high dose glucocorticoids are associated with increased cardiovascular events, it 6 is unclear whether lower doses (e.g., prednisolone <10 mg/day), commonly prescribed long-7 term, alter cardiovascular risk [10] . Some epidemiological studies have reported an increase 8 in cardiovascular events with low dose prednisolone, while others have reported no effect 9 [11, 12] . Furthermore, the sample size and duration of randomized-controlled studies of 10 glucocorticoid therapy in patients with rheumatoid arthritis are insufficient to assess 11 cardiovascular events [13, 14] .
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4
The measurement of circulating arginine metabolites is an alternative method to assess 1 endothelial function and cardiovascular risk. Asymmetric dimethyl arginine (ADMA) is a 2 competitive inhibitor of endothelial nitric oxide synthase (e-NOS), the enzyme that converts 3 L-arginine to citrulline and releases nitric oxide. ADMA is positively associated with 4 endothelial dysfunction [23] and cardiovascular mortality [24, 25] . Emerging evidence 5 suggests that other arginine metabolites also influence cardiovascular risk. Mono methyl 6 arginine (MMA), another inhibitor of e-NOS, and symmetric dimethyl arginine (SDMA), 7 which reduces L-arginine bioavailability, are also associated with atherosclerosis and 8 cardiovascular events [26] [27] [28] . L-arginine is also metabolized by arginase to ornithine and by 
Patients and methods
4
Subjects and study design 5 Subjects with rheumatoid arthritis aged 50 years or older were recruited from the 6 rheumatology outpatient clinic at Repatriation General Hospital, Adelaide, Australia and 7 healthy controls from the general community. We studied 18 subjects who had not been 8 administered any oral glucocorticoids for at least 6 months (non-GC users), 18 subjects 9 taking a stable continuous oral prednisolone dose of 4-10 mg/day for at least 6 months (GC 10 users) and 20 healthy controls with no history of inflammatory disease. The groups were 11 matched for age, sex and renal function and subjects on oral hypoglycaemic agents and /or 12 insulin were excluded from the study. First, we compared arginine metabolite concentrations 13 in non-GC users and controls to assess the effect of rheumatoid arthritis on arginine 14 metabolism. Secondly, non-GC users were studied before and after a 7 day course of oral 15 prednisolone 6 mg daily to determine the acute effects of prednisolone. Finally, baseline data 16 from non-GC users were compared with data from GC users to determine the chronic effects 17 of prednisolone. Corporation, Tokyo, Japan). The between-run coefficient of variation was 3.6 % at a CRP of as mean ± standard error of mean. Subject characteristics in the three groups were compared 13 using one-way analysis of variance. Non-GC users were compared to controls using unpaired 14 t-tests if normally distributed or Mann-Whitney U tests if the distribution was not normal.
15
Changes in variables in non-GC users after 7 days prednisolone were analysed using paired t-
16
tests. Hereafter in the manuscript these results are reported as the acute effects of 17 prednisolone. GC users were compared with baseline data from non-GC users using unpaired 18 t-tests if normally distributed or Mann-Whitney U tests if the distribution was not normal.
19
Differences between these two groups are reported in the manuscript as the chronic effects of 20 prednisolone. In cross-sectional analyses, if a variable was significant in univariate analysis it 21 was corrected for potential confounders using analysis of covariance. 
Results
5
Subject characteristics 6
There were no significant differences in sex, age, body mass index, eGFR, smoking, history 7 of hypertension, ischemic heart disease or diabetes between the three groups ( prednisolone in this patient group [21, 22] .
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In this study, patients with rheumatoid arthritis had higher concentrations of ADMA and 9 MMA than controls. Patients with rheumatoid arthritis also had higher plasma concentrations of arginine and of key variables (Table 1) . Finally, our findings cannot be translated to prednisolone doses of 7 >10 mg/day. Data are mean ± standard deviation.
4
GC, glucocorticoid; n, number of subjects with a specified variable; BMI, body mass index; 5 e-GFR, estimated glomerular filtration rate. Ischemic heart disease (n, (%)) 0 (0) 1 (6) 1 (6) 0.56 
